Literature DB >> 23259337

[Treatment of hepatocellular carcinoma].

Jacques Belghiti1.   

Abstract

HCC is frequent and difficult to treat, especially in patients with underlying chronic liver disease The risk of recurrence is very high. The best curative treatment for patients with limited tumors is liver transplantation (LT), an option restricted to rich countries and selected patients with a low risk of recurrence. Other curative treatments include partial liver resection in patients with excellent liver function, and radiofrequency ablation of tumors measuring less than 5 cm. Multiple tumors can be treated with transcatheter arterial chemoembolization or, more recently, 90Y radiotherapy. All these treatments may be combined in patients on the waiting list for LT Despite its potentially severe side effects, the new multikinase inhibitor sorafenib improves survival in the terminal phase.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23259337

Source DB:  PubMed          Journal:  Bull Acad Natl Med        ISSN: 0001-4079            Impact factor:   0.144


  1 in total

1.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.